agilon health (AGL) director granted 2,133 RSUs, now holds 56,242 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Mansukani Sharad reported acquisition or exercise transactions in this Form 4 filing.

agilon health, inc. director Sharad Mansukani received a grant of 2,133 shares of Common Stock in the form of restricted stock units. These units vest in full on June 2, 2027, contingent on his continued service as a director.

After this award, he beneficially owns 56,242 shares, which include restricted stock units and reflect the company’s 1-for-25 reverse stock split that became effective on March 30, 2026. This filing reflects routine equity compensation rather than an open‑market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mansukani Sharad

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,133	$0.00	--

Holdings After Transaction: Common Stock — 56,242 shares (Direct, null)

Footnotes (1)

Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director. The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026. Includes restricted stock units.

Key Figures

RSU grant size: 2,133 shares Post-transaction holdings: 56,242 shares Vesting date: June 2, 2027 +1 more

4 metrics

RSU grant size 2,133 shares Restricted stock units granted on June 2, 2026

Post-transaction holdings 56,242 shares Beneficially owned following the reported transaction

Vesting date June 2, 2027 Restricted stock units vest in full on this date

Reverse stock split ratio 1-for-25 Reverse split effective March 30, 2026

Key Terms

Restricted stock units, reverse stock split, beneficially owned

3 terms

Restricted stock units financial

"Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

reverse stock split financial

"reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026."

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

beneficially owned financial

"The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/04/2026 - 09:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mansukani Sharad

(Last)

(First)

(Middle)

C/O AGILON HEALTH, INC.

440 POLARIS PARKWAY, SUITE 550

(Street)

WESTERVILLE

OHIO

43082

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
agilon health, inc. [ AGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/02/2026		A		2,133⁽¹⁾	A	$0	56,242⁽²⁾⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Restricted stock units that vest in full on June 2, 2027, subject to continued service as a director.

2. The amount of securities beneficially owned following the reported transaction reflects the 1 for 25 reverse stock split of the Issuer's issued and outstanding common stock effective March 30, 2026.

3. Includes restricted stock units.

Remarks:

	/s/ Mimi Yang, as Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did agilon health (AGL) director Sharad Mansukani report in this Form 4?

He reported receiving 2,133 restricted stock units of agilon health common stock. The grant is compensation, not a market purchase, and increases his beneficial holdings while aligning his incentives with the company’s long-term performance and governance.

When do Sharad Mansukani’s new agilon health (AGL) restricted stock units vest?

The 2,133 restricted stock units vest in full on June 2, 2027. Vesting is conditioned on his continued service as a director, meaning he must remain on the board through that date to receive the underlying shares.

How many agilon health (AGL) shares does Sharad Mansukani own after this grant?

Following the award, he beneficially owns 56,242 shares of agilon health common stock. This figure includes restricted stock units and reflects the company’s 1-for-25 reverse stock split effective March 30, 2026, as described in the filing footnotes.

Is Sharad Mansukani’s Form 4 transaction a buy or sell of agilon health (AGL) stock?

The transaction is an acquisition through a grant of restricted stock units, not a buy or sell on the open market. It represents equity compensation awarded by the company rather than a discretionary stock trade by the director.

How did agilon health’s 1-for-25 reverse stock split affect this Form 4 for AGL?

The number of securities beneficially owned after the transaction reflects agilon health’s 1-for-25 reverse stock split. Effective March 30, 2026, this corporate action consolidated shares, and the reported post-transaction holdings are stated on the split-adjusted basis.